DC-CIK Immunotherapy

Phase 2Biologic

SShenzhen Second People's Hospital

DC-CIK Immunotherapy is one of 73 biologic programs targeting Safety and Efficacy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Safety and EfficacyUnknown status

Breast CancerActive, not recruiting

Safety and EfficacyPreclinical

Unknown status

Breast CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Blenoxane

Bristol-Myers Squibb

Preclinical

1 2

Spravato

WWim Janssens

Preclinical

2 3

DC-CIK Immunotherapy

SShenzhen Second People's Hospital

Phase 2

1 4

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 5

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 6

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

1 7

Tianeptine

Pfizer

Preclinical

1 8

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 9

Metfomin

UUniversity of Texas Southwestern Medical Center

Preclinical

1 10

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2033

Phase 2Active, not recruiting

Breast Cancer

NCT02491697

Clinical

Trials by Indication[1]

Breast Cancer1 trial

Immunotherapy Combined With Capecitabine Versus Capecitabine Monotherapy in Advanced Breast Cancer

Active, not recruiting·TThe First People's Hospital of Changzhou·Phase 2·NCT02491697·400 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Immune Therapy for Condyloma

Unknown status·SShenzhen Second People's Hospital·N/A·NCT03158480·80 enrolled

Malignant Mesothelioma1 trial

Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma

Terminated·—·Phase 1/2·NCT03393858·10 enrolled

Malignant Tumor1 trial

Gene Expression Profiling of Malignant Tumor Predict the Therapeutic Response of DC-CIK Immunotherapy

Completed·—·N/A·NCT01906632·50 enrolled

Gene Expression1 trial

Study of Gene Expression Profiling and Immunological Mechanism Affects the Response of Immunotherapy

Completed·—··NCT01884168·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for DC-CIK Immunotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DC-CIK Immunotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DC-CIK Immunotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shenzhen Second People's Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: SShenzhen Second People's Hospital

DC-CIK Immunotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2033

Trials by Indication[1]

Breast Cancer1 trial

Safety and Efficacy1 trial

Malignant Mesothelioma1 trial

Malignant Tumor1 trial

Gene Expression1 trial

References

Drug Info

Quick Facts

Related News